Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

High-Performance Calorimeter Enables Superior Materials Analysis and Development

By BiotechDaily International staff writers
Posted on 30 Apr 2013
Image: Shimadzu’s DSC-60 Plus series new differential scanning calorimeter (Photo courtesy of Shimadzu).
Image: Shimadzu’s DSC-60 Plus series new differential scanning calorimeter (Photo courtesy of Shimadzu).
A new, simple-to-operate, differential scanning calorimeter incorporates new technology designed to offer high sensitivity and resolution required for materials characterization in R&D and quality control applications for areas such as pharmaceuticals, polymers, etc.

Shimadzu (Kyoto, Japan) introduces their new thermal analyzer, the DSC-60 Plus series differential scanning calorimeter (DSC), for the analysis and development of high-performance, highly functional materials. In addition to top-class sensitivity and resolution, a new detector and a unique furnace construction achieve a noise level of less than 0.5 μW, providing a stable baseline from ultralow to high temperatures—across the entire measured temperature range (-140–600 °C). It also features a wide dynamic measurement range of ±150 mW (extended three times compared to previous Shimadzu instruments).

The DSC-60 Plus enables diverse and complex calorimetric measurements via simple operations. A cooling chamber with a liquid-nitrogen option permits easy measurements below room temperature (RT) - extremely convenient as it eliminates the need to install special accessories. A sample loading temperature function (SLTF) enables quick sample change during sequential analysis: while running a series of analyses below RT, the furnace temperature must be returned to near RT during sample replacement—the SLTF heats only the region around the sample when the sample is replaced, so that measurement can be rapidly resumed without moisture condensation.

The DSC-60 Plus is also eco-friendly. The newly designed furnace unit reduces energy consumption by over 20%, as measured when heating from RT to 300 °C at a 20 °C/minute heating rate (compared to previous Shimadzu instruments). When making measurements below RT, the liquid-nitrogen consumption savings exceed 30% (compared to previous Shimadzu instruments). The instrument footprint (W: 320 x H: 500 x D: 500 (mm)) has also been minimized.

The DSC-60 Plus series complies with various guidelines and regulations involving analytical laboratories, such as the PIC/S GMP guidelines, and electronic record/electronic signature (ER/ES) regulations and policies, including the US FDA 21 CFR Part11. In addition, it is compatible with various other analytical instruments and connected network systems, helping to ensure overall laboratory compliance.

Related Links:

Shimadzu



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.